BlackRock
IMMX icon

BlackRock’s Immix Biopharma IMMX Stock Holding History

BlackRock’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.27M Buy
468,377
+338,122
+260% +$2.48M ﹤0.01% 3891
2025
Q4 		$681K Buy
130,255
+87,187
+202% +$359K ﹤0.01% 4410
2025
Q3 		$90K Buy
43,068
+2,767
+7% +$6.64K ﹤0.01% 4852
2025
Q2 		$83.4K Buy
40,301
+28,477
+241% +$57.3K ﹤0.01% 4877
2025
Q1 		$19.9K Sell
11,824
-2,252
-16% -$4.25K ﹤0.01% 5093
2024
Q4 		$31K Buy
14,076
+73
+0.5% +$133 ﹤0.01% 5037
2024
Q3 		$20.9K Buy
14,003
+548
+4% +$1.1K ﹤0.01% 4931
2024
Q2 		$26.6K Sell
13,455
-5,866
-30% -$13.5K ﹤0.01% 4964
2024
Q1 		$59.3K Buy
19,321
+1,609
+9% +$6.23K ﹤0.01% 4837
2023
Q4 		$123K Sell
17,712
-279
-2% -$1.26K ﹤0.01% 4755
2023
Q3 		$61.5K Buy
17,991
+2,343
+15% +$5.49K ﹤0.01% 4967
2023
Q2 		$42.1K Buy
+15,648
New +$32.8K ﹤0.01% 5094
2022
Q2 		– Sell
-9,415
Closed -$22K – 5910
2022
Q1 		$22K Buy
+9,415
New +$35K ﹤0.01% 5556

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BlackRock's IMMX Position: Q1 2026 in Review

BlackRock increased its Immix Biopharma (IMMX) stake by 260% in Q1 2026, buying an estimated $2.48M and bringing the position to 468,377 shares worth $4.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

BlackRock first reported a position in IMMX in Q1 2022 and has held it in 13 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • BlackRock held 468,377 shares of Immix Biopharma worth $4.27M as of Q1 2026.
  • BlackRock bought 338,122 Immix Biopharma shares in Q1 2026, an estimated $2.48M.
  • Immix Biopharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3891 holding.
  • BlackRock first reported a position in Immix Biopharma in Q1 2022 and has held it in 13 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.